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Four inhibitors of eukaryotic topoisomerases were investi-
gated for genotoxic effects in the wing spot test of Drosophila
melanogaster. As a somatic mutation and recombination
test (SMART) this assay assesses mitotic recombination
and mutational events of various kinds. We studied campto-
thecin as a topoisomerase I inhibitor, as well as ellipticine
as an intercalating inhibitor and teniposide and etoposide
as two non-intercalating inhibitors of topoisomerase II.
Wing spots were induced in flies trans-heterozygous for
the recessive wing cell markers multiple wing hairs (mwh)
and flare (flr3) as well as in flies heterozygous for mwh and
the multiply inverted TM3 balancer chromosome. All four
compounds proved significantly genotoxic in this test The
spot induction frequencies formally standardized to the
millimolar unit of exposure dose decreased in the order
camptothecin > teniposide > ellipticine S etoposide in
the mwhJflr3 inversion-free genotype. In the mwh/TM3
genotype, in which mitotic crossing over is suppressed
because of the inversion-heterozygosity, the observed spot
frequencies were considerably reduced, but to different
extents. In this genotype, spot induction by ellipticine was
not statistically significant, and it was determined that
>99% of the spots are due to mitotic recombination in
mwh/flr3 flies. For the other compounds, spot induction in
the inversion-heterozygous genotype was significant The
relative contribution of recombination to total spot induc-
tion in the inversion-free genotype was 88% for campto-
thecin. It was significantly lower for the two epipodo-
phyllotoxins teniposide (71%) and etoposide (59%). Only
suggestions can be proffered at present as to how these
proportions could be related to the primary damage pro-
duced by the respective compounds on the chromosomes.
Introduction
The somatic mutation and recombination tests (SMART) of
Drosophila melanogaster developed in recent years are sensit-
ive and inexpensive in vivo assays capable of detecting a great
variety of genotoxins (WUrgler and Vogel, 1986). The in vivo
assays with the insect Drosophila may be viewed as a link
between micro-organismal in vitro and mammalian in vivo
genotoxicity test systems.
The wing spot test is one of the two SMART assays currently
in use. Essentially, it is based on the induction of mutant spots
(clones) that arise from loss of heterozygosity in the cells of
developing animals which are heterozygous for recessive wing
cell marker mutations. Such mutant spots can be due to
different mutation and recombination mechanisms (Graf et al.,
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1984). To evaluate to what extent the mechanism of mitotic
recombination contributes to wing spot induction, we rely
upon the analysis of the two genotypes of which the fly
progeny recovered in the wing spot test are composed, i.e.
marker heterozygotes for the wing cell marker mutations
multiple wing hairs (mwh) and flare-3 (flr3) and inversion
heterozygotes mwh/TM3 in which mitotic crossing over is
suppressed (Frei et aL, 1992a).
Chemicals which produce genotoxic effects by mechanisms
other than covalent binding to DNA are of particular interest
in the evaluation of genotoxicity test procedures as such
compounds may act as inhibitors of enzymes and thereby
cause genetic damage in an indirect way. Because enzyme
inhibition may depend on a specific affinity between the
inhibiting and the inhibited molecules there is the possibility of
a species-specific response due to macromolecular evolutionary
divergence between homologous proteins in different organ-
isms. Within the frame of a large validation programme for
the wing spot test, we set out to investigate particularly
chemicals which interact with enzymes of DNA metabolism
and replication for possible genotoxic activity. In this study,
we report on topoisomerase inhibitors.
Topoisomerases are important for various DNA transactions,
such as replication, transcription and recombination (cf. reviews
by Liu, 1989; Osheroff, 1989a; Ferguson and Baguley, 1994).
By their capacity of cleaving transiently the phosphodiester
bonds in DNA strands they allow for single- or double-strand
passage, auto-rotation of the double helix and relief from
torsional constraints in DNA coiling arising, for instance, from
helical unwinding during DNA or RNA synthesis. Topoisomer-
ase II has also functions in mitosis and meiosis—in mitosis
particularly for chromosome condensation and the separation
of interlocked double-stranded DNA at segregation (Buchenau
et al., 1993; Ferguson and Baguley, 1994).
We were interested to compare inhibitors of topoisomerase I
(single-strand cleaving enzyme) and topoisomerase II (double-
strand cleaving enzyme) with respect to possible genotoxic
effects.
Both types of topoisomerase are well characterized in
the test organism D.melanogaster. Topoisomerase I shows
extensive homology to the corresponding polypeptides of yeast
species and man, but differs from these by a serine- and
histidine-rich 200 bp N-terminal stretch (Hsieh et al, 1992).
Like that in yeast and man, topoisomerase II of Drosophila is
a homodimer and has subunits of comparable size and shape
(Shelton et al, 1983). The homology between D.melanogaster
and yeast species is almost as close as that between the
two yeast species Saccharomyces cerevisiae and S.pombe
(Osheroff, 1989a). There are correspondences of the
Drosophila topoisomerase II to gyrase (the heterotetrameric
bacterial type II topoisomerase), but the homologies are
regionally very restricted and loose (Wyckoff et al, 1989).
The chemicals investigated in this study (Figure 1) include
three topoisomerase II inhibitors: the intercalating agent
ellipticine, as well as the two non-intercalating podophyllotoxin
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Fig. 1. Chemical structures of the four topoisomerase inhibitors studied.
derivatives teniposide and etoposide. The fourth compound is
camptothecin, which is well known as a prototype topoisomer-
ase I inhibitor. We opted for chemicals which differed in their
DNA and enzyme binding (Liu, 1989; Ferguson and Baguley,
1994). Different genotoxic actions may lead to different
reaction patterns in the wing spot test, since this SMART
assay is considered sensitive to the induction of various types
of genetic endpoints, such as mitotic recombination, deletion,
segmental aneuploidy and point mutation (Haynie and Bryant,
1977; Graf et al, 1984). We wanted to know whether these
agents showed genotoxic activity in the cells of the proliferating
wing primordia of Drosophila and, if so, to what extent they
induced mutational and recombinational events.
Materials and methods
Chemicals
Ellipticine (CAS no. 519-23-3) and camptothecin (CAS no. 7689-03-4) were
purchased from Sigma (St Louis, MO). Etoposide (CAS no 33419-42-0) was
a gift from Dr R.D.Snyder (Stauffer Chemicals, Farmington, CT)- Teniposide
(CAS no. 29767-20-2) was tested as the clinical preparation Vumon® (Bristol-
Myers, Princeton, NJ) containing 10 mg/ml of teniposide; the two tested
concentrations of 0.1 and 0.05 mg/ml correspond to 0.152 and 0.076 mM
respectively. Solutions and dilutions of the compounds were made with 5%
ethanol and 5% Tween-80 in water except for Vumon®, which was diluted
with water.
Wing spot test
For the wing spot test, we adopted the methods and screening criteria of Graf
et al. (1984), except that other strains were used for the outcross. Eggs were
collected for 8 h from a cross between mwh females and fl^/TMl, ri pP sep
l(3)89Aa bx34* e B(f males [for genetic symbols and descriptions see Lindsley
and Zimm (1992)]. Progeny were raised at 25°C. For the first 72 h they were
kept on standard commeal medium copiously enriched with baker's yeast and
were then fed with the chemicals in the experimental vials during the remainder
of larval life (-48 h). Vials contained 1.5 g of Drosophila Instant Medium
(Carolina Biological Supply, Burlington, N Q rehydrated with 5 ml of the
test solutions.
The wings of the hatched flies were examined at X400 magnification for
the occurrence of mutant spots (clones) on the phenotypically wildtype wing
blade. Wings of mwh/flr3 marker heterozygous flies were screened for single
spots (phenotype mwh or flr3) and twin spots (phenotypes mwh and flr3 in
adjacent clones), while on the inversion-heterozygous mwh/TM3 wings, only
mwh single spots can be found, as the multiply inverted TM3 balancer
chromosome does not carry flr3 or any other suitable wing cell marker mutation.
Statistical evaluation
For an unbiased comparison of the induction frequencies in the two genotypes,
only mwh clones in mwh single spots and in twin spots were taken into
consideration (cf. Frei et al., 1992a). The mwh clone induction frequencies
per cell and per cell division were calculated with and without clone size
corrections according to the latter reference.
For statistical testing, the decision procedure of Frei and Wiirgler (1988)
was applied. As customary for the evaluation of wing spot data (Graf et al.,
1984), the following classes among the total of spots are distinguished: small
single spots (1-2 cells in size), large single spots (3 cells or larger) and twin
spots. This classification is biologically meaningful (Frei and WUrgler, 1988).
From the statistical point of view, it should be pointed out, however, that the
three spot categories are not equivalent with respect to statistical power, i.e.
if used in significance testing, particularly to evaluate chronic exposure data,
small single spots represent the most sensitive and twin spots the least sensitive
of the three criteria (Frei and WUrgler, 1995).
Results
The results of wing analysis are shown in Table I. Historical
and pooled controls show that water and the Tween-80/ethanol
solvent used as carriers in the experiments give very similar
spontaneous spot frequencies and that in mwh/TM3 inversion-
heterozygotes the recovery of mwh clones is reduced to about
one-third of the frequency found in mwh/flr3 inversion-free
marker heterozygotes. Because concurrent controls showed
only a few spots, the data from the pooled large controls were
used for control corrections in the determination of clone
induction frequencies to minimize the influence of stochastic
fluctuations.
For significance testing, however, the spot scores in treated
groups were always compared with the corresponding concur-
rent control. In the mwh/flr3 genotype, all four compounds
tested showed clear positive effects, with significant and
exposure dose-related induction for all spot categories con-
sidered.
For ellipticine, exceptionally, we found a reduced frequency
of spots at the highest exposure concentration tested (8 mM)
compared with the next highest concentration (4 mM), but in
the range of 0.5-4 mM there was a steady increase with dose
in the frequency of all spot categories over almost an order of
magnitude in exposure concentration. The reduction at the
highest concentration could be a selection effect due to toxicity
of the compound since ~50-60% of the animals did not reach
the adult stage at the 8 mM exposure level. However, a
repellent effect or growth inhibition could also be responsible
for the decline, because we noted with this compound and
at this concentration that the majority of the pupae were
underdeveloped in size. This was not the case at lower
concentrations, whereas some pupal lethality was still observed
(20-50% approximately in the exposure concentration range
0.5-4 mM).
With teniposide, all animals died at exposure concentrations
of 0.25-1 mg/ml, while at the two genotoxic exposure concen-
trations of 0.05 and 0.1 mg/ml the pupal lethalities were
estimated as 20 and 70% respectively.
Etoposide was not visibly toxic in the tested concentration
range of 0.5-2 mM. Solubility problems were encountered
with this compound which had to be tested as a suspension.
It is possible that the comparatively strong genotoxic response
recorded at the 2 mM exposure in comparison with the lower
exposure levels reflects an unequal exposure of the growing
larvae owing to a non-homogeneous distribution of the com-
pound in the test medium.
Solubility problems were also encountered with campto-
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thecin, but the five highest concentrations assayed (0.5-7 mM)
were so toxic that flies barely survived. Only wings from
lower exposure levels could be analysed; at 0.25 mM concentra-
tion there were roughly 70% surviving flies, while at 0.05 and
0.1 mM concentrations survival was similar to the controls.
Particularly striking with this compound, a dose-dependent
delay in larval development was observed virtually throughout
the whole exposure range, but particularly at the strongly toxic
exposure levels. As large clones are considered to reflect
induction early in ontogeny, developmental retardation in
combination with chemical instability may explain the rela-
tively large size of the clones induced with this chemical
(camptothecin produced the largest clones; see below).
If possible, we test potential mutagens with a geometric
series of dilutions, try to attain the maximum tolerated dose
(MTD), and examine MTD, MTD/2, MTD/4 etc. for genotoxic
effects. In the present study, the toxic limit was reached
with teniposide (>0.15 mM), camptothecin (>0.2 mM) and
ellipticine (>8 mM). General toxicity can be quite unrelated
to genotoxicity: for instance, at the non-toxic 2 mM exposure
concentration, etoposide was more effective in inducing wing
spots than teniposide at its 0.15 mM MTD. The genotoxic
efficiency (denned here as genotoxicity at the MTD) was
lowest for teniposide, significantly higher for camptothecin
and in turn significantly higher for ellipticine (Table I, Figure
2). Because etoposide was not toxic at the concentrations
tested, we do not know the MTD for this compound, but on
account of the present data (Figure 2) it can be concluded that
its genotoxic efficiency must be significantly higher than that
of the analogue teniposide.
Genotoxicity and recombinagenicity
As a significant induction of twin spots was obtained for all
four compounds, it is proved that they are recombinagenic.
While this criterion is valid for qualitative judgements, the
relative frequency of twin spots identified among the total of
spots recovered does not seem a suitable basis for the quanti-
tative estimation of the relative recombinagenic potency of
genotoxic compounds. It is well known that flr mutations are
not or not fully expressed phenotypically in small clones
(Szabad et al, 1983). This makes the correct identification of
small twin spots difficult.
In the present experiments, the identification of twin spots
was clearly correlated with spot size. In Figure 3 we used the
geometric mean of mwh clone size as a measure of average
spot size. The graph shows that in controls, clones are small
on average and that only ~10% of the spots recovered are
identified as twin spots. In the treatment series, clones were
larger and the proportion of twin spots scored was greater.
Because of the uncertainties which arise from the spot size
dependence of twin spot identification, it is far more preferable
to estimate the relative contribution of recombination to spot
induction from a comparison of the two genotypes mwh/flr3
and mwh/TM3, which constitute the two types of offspring
from the outcross used in the wing spot test. In the latter
genotype recombination is suppressed due to inversion-
heterozygosity and therefore the difference in mwh clone
induction frequencies between the two genotypes can be used
to estimate the contribution of recombination to clone induction
in the former, inversion-free genotype.
Owing to the reduced spot induction frequency in mwh/
TM3 flies compared with mwh/flr3 ones, there were in general
more inconclusive results at the lower exposure concentrations
in the mwh/TM3 genotype than in the mwh/flr3 flies (Table I).
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Fig. 2. Double logarithmic plot of mwh clones recovered per wing at
different exposure concentrations: camptothecin (Cam, #O) ; ellipticine (Ell,
• O ) ; teniposide (Ten, • • ) ; etoposide (Eto, AA). Frequencies (±SE) are
shown for mwh/flr3 marker-heterozygous flies (full symbols) and mwh/TMi
inversion-heterozygous flies (italics, open symbols). About 3 mwh clones
per wing correspond to a 10-fold increase (/IOX) over the spontaneous level
in mwh/flr3 flies.
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Fig. 3. Correlation between twin spot recovery and clone size. The plot is
based on uncorrected observation data in the different exposure series as
reported in Table I.
At the higher exposure levels, however, etoposide, teniposide
and camptothecin showed positive results, although for campto-
thecin the result was significant only for the small single spots
(1-2 cells in size) and for the total of spots, while the large
single spots (3 cells or larger in size) were more frequent than
in the concurrent control but not significantly so.
For ellipticine, by contrast, no significant spot induction
was found in the inversion-heterozygous flies at any of the
five concentrations tested which had given clearly positive
results in the inversion-free genotype. Therefore, it appears
that with ellipticine all or nearly all spots recovered in
inversion-free mwh/flr3 flies are due to reciprocal recom-
bination.
For a quantitative comparison of spot induction by the four
compounds in the two genotypes we unified the data to
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TaMe I. Statistical significance of wing
'•Controls and
compounds
Genotypes
'Water (historical
mwh/flr3
mwh/TM3
25% Tween-80 +
mwlt/flr3
mwlt/TM3
Cone.
(mM)
No. of
wings (N)
and pooled controls)
790
504
5% ethanol (historica
'Teniposide (Vumon)
mwlt/flr3
mwh/TM3
2Etoposide
mwh/flr3
mwlt/TM3
2Ellipticine
mwlt/flr3
mwli/TM3
^Camptothecin
mwlt/flr3
mwlt/TM3
0
0.076
0.152
0
0.076
0.152
0
0.5
1
2
0
1
2
0
0.5
1
2
4
8
0
0.5
1
2
4
8
0
0.05
0.10
0.25
0
0.05
0.10
382
100
48
48
38
48
48
26
48
48
48
48
48
42
48
48
48
48
48
44
20
28
22
20
40
78
48
48
48
48
40
24
16
22
spot induction by teniposide, etoposide, ellipticin and camptothecin after feeding
Spots per wing (no. of spots) statistical diagnosis"
Small single spots
(l-2cells)b
m = 2
0.24(189)
0.11 (53)
and pooled controls)
0.21 (80)
0.08 (8)
0.17 (8)
0.96 (46) +
0.84 (32) +
0.06 (3)
0.44 (21) +
0.50 (13) +
0 19 (9)
0.35 (17) i
0.52 (25) +
2.83 (136) +
0.08 (4)
0.45 (19) +
1.38 (66) +
0.19 (9)
0.42 (20) +
1.65 (79) +
4.83 (232) +
8.66 (381) -f-
7.70(154) +
0.07 (2)
0.23 (5) .
0.10 (2) i
0.08 (3) i
0.13 (10) i
0.19 (9) i
0.19 (9)
1.04 (50) +
2.33 (112) +
2.60(104) +
0.08 (2)
0.25 (4) i
0.45 (10) +
Large single spots
(>2 cells)6
m = 5
0.03 (27)
0.01 (3)
0.04 (14)
0.03 (3)
0.02 (1)
0.38 (18) +
1.00 (38) +
0.06 (3)
0.02 ( 1 ) -
0.31 (8) +
0.02 (1)
0.15 (7) +
0.23 (11) +
2.15 (103) +
0.04 (2)
0 . 1 0 ( 4 ) i
0.67 (32) +
0.06 (3)
0.38 (18) +
1.21 (58) +
2.23 (107) +
4.00 (176) +
2.00 (40) +
0.04 (1)
0.00 (0) i
0.00 (0) i
0.05 (2) i
0.08 (6) i
0.02 (1) i
0.02 (1)
1.29 (62) +
1.75 (84) +
3.78 (151) +
0.00 (0)
0.06 ( l ) i
0.14 (3) i
Twin spots
m = 5
0.03 (20)
g
0.03 (10)
*
0.02 (1)
0.44(21) +
0.55 (21) +
i
0.04 (2)
0.08 (4) i
0.15 (7) i
1.35 (65) +
g
0.02 (1)
0.29 (14) +
0.54 (26) +
1.35 (65) +
2.23 (98) +
1.50(30) +
t
0.00 (0)
0.65 (31) +
1.02 (49) +
2.15 (86) +
g
Total spots
m = 2
0.30 (236)
0.11 (56)
0.27 (104)
0.11 (11)
0.21 (10)
1.77 (85) +
2.39 (91) +
0 13 (6)
0.46 (22) +
0.81 (21) +
0.25 (12)
0.58 (28) +
0.90 (43) +
6.33 (304) +
0.13 (6)
0.55 (23) +
2.04 (98) +
0.27 (13)
1.08 (52) +
3.40(163) +
8.42 (404) +
14.89 (655) +
11.20(224) +
0.11 (3)
0.23 (5) i
0.10 (2) i
0.13 (5)i
0.21 (16) i
0.21 (10) i
0.21 (10)
2.98(143) +
5.10(245) +
8.52(341) +
0.08 (2)
0.31 (5) i
0.59 (13) +
to mwh/flr3
Total mwh
clones0 (n)
234
56
103
11
9
83
89
6
22
21
12
28
43
300
6
23
98
12
52
158
395
641
221
3
5
2
5
16
10
10
142
241
336
2
5
13
marker heterozygotes and
Mean
clone
mwh
size
class"1 (0
1.94
1.57
2.01
2 45
2.33
2.66
2.92
4.00
1.50
2.43
2.08
2.71
2.30
2.69
3.00
1.96
2.28
2.42
2.73
2.50
2.33
2.33
2.16
2.00
1.20
1.50
2.40
2.25
1.50
1.50
3.18
2.84
3.49
1.50
2.00
1.69
[2.81]
[3.06]
[1.48]
[2.57]
[3.32]
[2.43]
[2.72]
[1.83]
[2.27]
[2.97]
[2.54]
[2.34]
[2.34]
[2.17]
[0.02]
[12.00]
[2.00]
[2.01]
[0.43]
[3.30]
[2.89]
[3.54]
[1.75]
[1.52]
Clone
(per 1
mwh/TM3
induction
inversion heterozygotes
frequencies
03 cells per cell division/
Without size correctionde With t
(n/NC
1.21
0.46
1.11
0.45
0.77
7.09
9.60
0.51
1.88
3.31
1.02
2.39
3.67
25.61
0.51
2.24
8.37
1.02
4.44
13.49
33.73
59.71
45.29
0.44
0.93
0.41
0.51
0.84
0.85
0.85
12.12
20.58
34.43
0.34
1.28
2.42
)
[5.87]
[8.38]
[1.42]
[2.85]
[1.29]
[2.57]
[24.51]
[1.79]
[7.92]
[3.33]
[12.39]
[32.62]
[58.60]
[44.18]
[0.48]
[-0.04]
[0.06]
[0.39]
[0.40]
[11.02]
[19.47]
[33.32]
[0.83]
[1.97]
(2f-2
1.16
0.34
l.ll
0.62
0.97
11.22
18.18
2.05
1.33
4.46
1.09
3.92
4.53
41.32
1.02
2.18
10.13
1.37
7.37
19.08
42.37
75 17
50.70
0.44
0.53
0.29
0.68
1.00
0.60
0.60
27.53
36.79
96.57
0.24
1.28
1.96
lone-size correction'1*
)X(nWQ
[10.32]
[17.53]
[0.99]
[4.22]
[3.21]
[3.45]
[40.39]
[1.60]
[9.52]
[6.53]
[18.05]
[41.29]
[74.09]
[49.59]
[0.12]
[-41.97]
[0.06]
[0.39]
[0.14]
[27.15]
[35.97]
[96.70]
[0.70]
[1.41]
X
Trei
 and
"*]I
3.
s-
Table I. Continued
'•^Superscript numbers refer to the corresponding pooled and historical controls.
•"Statistical diagnoses according to Frei and WUrgler (1988): +, positive; -, negative; 1, inconclusive, m, multiplication factor for the assessment of significantly negative results. Significance levels a
0.05.
blncluding rare flr3 single spots.
Considering mwh clones from mwh single spots and from twin spots.
^Numbers in square brackets are induction frequencies corrected for spontaneous incidence estimated from the large histoncal and pooled controls.
CC 24 400, i.e. approximate number of cells examined per wing.
'Calculated according to Frei et al. (1992a).
''Only mwh single spots can be observed in mwh/TM3 heterozygotes as the balancer chromosome TM3 does not carry a flr mutation.
Table II. Standardized mwh clone induction frequencies per millimolar unit of exposure concentration and the prevalence of recombination events*
Compounds
Teniposide
Etoposide
Ellipticine
Camptothecin
mwli/flr marker
Standardized
frequency*1
(mwh clones
per 103 cells
per mM)
{ft)
63.7
8.1
11.5
162.6
heterozygotes
Mean clone
size class
(f/>
2.95
2.72
2.35
3.27
Geometric
mean of clone
size0 (cells)
(2"- ' )
3.85
3.30
2.55
4.84
Standardized
frequency per
103 cells,
corrected for
clone sized
(f;=2"-2xf,)
122.8
13.4
14.6
393.3
mwli/TM3 inversion heterozygotes
Standardized
frequency*
(mwh clones
per 105 cells
per mM)
to)
18.8
3.3
0.08
18.9
Mean clone
size class
«*)
2.05
2.19
1.05
1.57
Geometric
mean of clone
size0 (cells)
( 2 * - 1 )
2.07
2.29
1.03
1.49
Standardized
frequency per
105 cells.
corrected for
clone sized
(fh=2n -2Xfh)
19.5
3.8
0.04
14.0
Recombination
without clone
size correction
(1 -fh/f,)X\(X
71
59
99.3
88
(%)
with clone size
correction"1
) (1 -fh/f,) X 100
84
72
99.7
96
aAll values arc control corrected. Frequencies in mwh/flr3 marker-heterozygotes and mwh/TM3 inversion-heterozygotes are calculated with and without clone size correction; accordingly, somewhat different
estimates are obtained for the relative contributions of recombination to the totals of clone induction.
kClone frequencies per wing divided by the number of cells examined per wing (24 400) estimate frequencies per cell and per cell division in chronic exposure experiments (Frei and WUrgler, 1988).
c
 Geometric mean and ^ corrections calculated according to Frei et al. (1992a).
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formally equimolar standardized values. The observed mwh
clone numbers in the two genotypes at each exposure level
(Table I) were corrected by subtraction of the estimated
number of spontaneous clones, so that the corrected frequencies
corresponded to estimated frequencies of induced spots. The
respective pooled and historical control frequencies and the
numbers of wings analysed in the different treatment series
served as the basis for this correction. An approximate average
induction frequency per millimolar unit of exposure concentra-
tion was then calculated by linear extrapolation combining the
results from the different exposure levels for each compound.
The results are shown in Table II as standardized mwh clone
induction frequencies per millimolar concentration, per cell
and per cell division.
The same correction procedure was also used for the data
underlying Figure 4a-e, except that the clones were arranged
into size classes and the standardized frequencies in this case
are given as clone induction frequencies per wing. In Figure
4f the spontaneous clone frequencies are given for the pooled
controls. Figure 4a and e could not be drawn to the same scale
as the other illustrations, because camptothecin and teniposide
were genotoxic at comparatively low exposure concentrations.
For comparison, the data for mitoxantrone are redrawn from
Frei et al. (1992a) in Figure 4d.
The standardized clone induction frequency per millimolar
exposure unit was highest for camptothecin. With teniposide
it was ~3 times, with ellipticine about 15-25 times and with
etoposide ~2O-3O times lower than with camptothecin. For
O>
Teniposide (Vumon)
mwh/fir
mwfi/TM3
Etoposide
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Fig. 4. Clone size distributions and mwh clone induction frequencies standardized to the millimolar exposure concentration unit in mwh/flr3 marker-
heterozygous flies and in mwh/TM3 inversion-heterozygous flies. Frequencies are control-corrected except in (f). Mitoxantrone data (d) are redrawn from Frei
et al. (1992a).
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equal effect exposures similar relationships are found. Frequen-
cies of ~3 mwh clones per wing correspond to an ~ 10-fold
increase (fiox) o v e r the spontaneous control frequency. For
the / | ox level, the respective approximate exposure doses are
0.05 mM for camptothecin, 0.15 mM for teniposide, 1 mM
for ellipticine and 1-2 mM for etoposide, as shown in Figure
2. The graph also illustrates that at the/|Ox and other exposure
levels ellipticine, camptothecin and teniposide differ signifi-
cantly among each other in their respective reductions in clone
frequency (mwh/TM3 < mwh/flr3). However, on account of
means and standard errors, the difference in reduction between
the epipodophyllotoxins teniposide and etoposide is not
statistically significant and may be fortuitous.
The comparison of the two genotypes demonstrates that
mitotic recombination is the prevalent mechanism of wing spot
induction. Ellipticine and camptothecin appear as exclusive or
strong recombinagens respectively. Teniposide and etoposide
are preferentially recombinagenic, but some 30—40% of the
spots are of non-recombinational origin. In Table II the
estimations of the proportions of clone induction attributed to
recombination differ somewhat, depending on whether clone
size corrections are applied or not in the calculations, but the
general conclusions remain unaffected by this.
Spot size
The spot size distributions in Figure 4a-e show that in mwh/
flr3 flies, clones are larger than expected (mean mwh clone
size > 2 cells) and therefore clone size corrections in Table
II lead to increased standardized frequencies compared with
the estimates obtained without size correction [for theoretical
considerations see Frei et al. (1992a)]. This was most pro-
nounced for the relatively large clones induced by campto-
thecin, which is known to be chemically unstable in its lactone
ring and for which this type of correction seems particularly
appropriate. But also for the other compounds the clone size
correction leads to increased estimates. This reflects probably
a reduced exposure of the cells towards the end of imaginal
disk development. Shortages relative to theoretical expectation
in the first size class (comprising <50%) and to some extent
in the second clone size class (comprising <25% of the total
of mwh clones) probably mean that the clones in the small
size classes (1-2 cells) have reduced frequencies, because for
these the time of induction is during the last and penultimate
mitotic divisions in the pupa when the drug uptake has ceased.
For the compounds which are able to induce wing spots in
the mwh/TM3 inversion-heterozygous genotype (Figure 4a-e),
mwh clones are smaller on average than in the inversion-free
mwh/flr3 marker heterozygotes. It has been postulated for
mitoxantrone that a majority of the small clones recovered in
mwh/TM3 flies may represent cases of induced segmental
aneuploidy with reduced proliferation capacity (Frei et al,
1992a). The reduction in clone induction frequency in the
mwh/TM3 flies compared with the mwh/flr3 flies is also less
pronounced for the two smallest clone size classes than for
the larger size classes, which is consistent with the idea that
inversion-heterozygosity only suppresses mitotic crossing over
but not the induction of deletions and other segmentally
deficient chromosomal aberrations, enabling a hemizygous
mwh manifestation owing to the uncovered recessive mwh
mutation.
Discussion
The SMART tests of Drosophila are versatile genotoxicity test
systems detecting a great variety of genotoxins belonging to
different chemical classes, including promutagens requiring
enzymatic bioactivation. Some promutagens, such as procarba-
zine, hexamethylphosphoramide (HMPA) or the group of
pyrrolizidine alkaloids, which are genotoxic in mammalian
cells but whose detection poses problems in bacterial genotox-
icity test systems, are readily detected by the SMART assays
in Drosophila (for refs see Wurgler and Vogel, 1986; Frei
et al, 1992b). Here we study four topoisomerase inhibitors
for their effects in the wing spot test. This seemed an interesting
group of compounds, because their effects depend on enzymes
for which there is evidence of significant evolutionary diver-
gence particularly between prokaryotes and eukaryotes, but
possibly also between lower and higher eukaryotes. The
four topoisomerase inhibitors studied proved genotoxic in the
Drosophila wing spot test in agreement with genotoxicity in
mammalian and human cells, where they induce chromosome
aberrations and sister chromatid exchanges (Bhuyan et al,
1972; Huang et al, 1973; Chen et al, 1984; DeMarini et al,
1987a; Moore et al, 1987; Maraschin et al, 1990; Agarwal
et al, 1994).
Molecular effects of topoisomerase poisons
For the type of inhibitors functioning as topoisomerase poisons
(Ferguson and Baguley, 1994), it appeared that an early event
of drug action is the formation of an intermediate called
the trapped cleavable complex, which represents the drug-
stabilized ternary complex between DNA, the covalently bound
topoisomerase and the inhibitor. While in the non-inhibited
state the strand breaks catalysed by the enzymes are transient,
they are not religated in the trapped complex (cf. Liu, 1989;
Ferguson and Baguley, 1994; Ralph et al, 1994). The cleavage
can be visualized by molecular biological methods following
treatment of the complexes with rapid protein denaturants
which reveal DNA single- and double-strand breaks associated
with bulky protein (i.e. topoisomerase) adducts.
Topoisomerase inhibitors genotoxic in Drosophila
The wing spot test of Drosophila apparently detects this
condition adequately and therefore seems to be a good predictor
for this type of genotoxic activity. Besides teniposide, etopo-
side, ellipticine and camptothecin, other topoisomerase inhib-
itors have been studied previously in the eye and wing SMART
assays of Drosophila. The intercalating agents adriamycin
(doxorubicin), daunomycin (daunorubicin) and mitoxantrone
gave positive results and were recombinagenic as they signifi-
cantly increased the frequency of twins spots (Frei etal, 1985,
1992a; Clements and Vogel, 1988).
Mitotic recombination, and single and twin spots in the wing
spot test
The relative frequency of twin spots may give some idea of
the recombinagenicity of a compound. Genotoxic chemicals
can give quite different results in this respect (Ramel and
Magnusson, 1992). The marker gene mwh is located at the tip
of the left arm of chromosome 3 (section 61E2-62A3). The
cytological locations of neighbouring genes place fir roughly
to the middle (section 69) of the left arm of chromosome 3
[cf. Lindsley and Zimm (1992) for map positions]. Under the
assumption that mitotic crossing over is proportional to the
physical distance on the chromosome between centromere and
marker genes (Becker, 1976), one would expect ~50% twin
spots (recombination between flr and the centromere) and 50%
mwh single spots (recombination between mwh and flr) if all
spots were due to mitotic crossing over. For chemicals such
as chromium(VI)oxide or ethylene oxide, twin spot frequencies
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of 40—45% have been reported and for the former it was
determined that >90% of the wing spots are due to mitotic
recombination (Graf et al, 1992; Ramel and Magnusson,
1992). However, with the four topoisomerases studied, twin
spot recovery was lower and not much different between the
compounds. On average 26, 22, 16 and 23% of the induced
spots were recovered as twin spots following exposure to
teniposide, etoposide, ellipticine and camptothecin respectively
(summarized from Table I).
Quantitation of recombinagenicity
The present data have shown that twin spot identification
depends on clone size. Ramel and Magnusson (1992) have
already pointed out that for chemicals producing predominantly
small spots, the lack of expression of the fir genotype in small
clones can lead to serious biases, because small twin spots
cannot be readily identified.
For an unbiased evaluation of recombinagenicity, we there-
fore prefer to compare the mwh clone frequencies in the two
genotypes mwh/flr and mwh/TM3. The difference in clone
induction between the two genotypes is a quantitative measure
of recombinagenicity. In this way, the relative contribution of
mitotic crossing over to total spot induction has been deter-
mined previously for mitoxantrone (Frei et al, 1992a). It was
estimated that 68% of the clones resulted from mitotic crossing
over (cf. Figure 4d). The four topoisomerase inhibitors pres-
ently studied differ from each other. In a comparison of
recombinational to non-recombinational origin of induced
clones, ellipticine ranks highest (almost 100% clones by
recombination), followed by camptothecin (88%), teniposide
(71%), and etoposide (59%). The difference between teniposide
and etoposide was not statistically significant, however.
Surprisingly, the two intercalating topoisomerase n inhib-
itors ellipticine (this study) and mitoxantrone (Frei et al,
1992a) are dissimilar in this respect. Whereas ellipticine
appears as an almost exclusive recombinagen, mitoxantrone is
preponderantly recombinagenic but with a significant propor-
tion of spots arising from mechanisms other than recombination
(cf. Figure 4c and d).
The clone induction pattern of mitoxantrone resembles more
that of the two non-intercalating topoisomerase II inhibitors
teniposide and etoposide. Notwithstanding that the treatments
revealed differences in genotoxic effectiveness, the clone size
distributions are similar for the three compounds and the
proportions of clone induction in the two genotypes indicate
that ~60-70% of the clones are due to recombination (cf.
Figure 4a, b and d).
Non-disjunction in SMART analysis
As topoisomerase II has functions in mitosis which are
important for chromosome segregation (cf. Ferguson and
Baguley, 1994) the question may be raised as to whether some
of the wing spots recovered from treatment with topoisomerase
II inhibitors could be due to induced non-disjunction and
represent clones monosomic for recessively marked chro-
mosomes.
There is evidence that chemicals able to interfere with the
mitotic apparatus can induce wing spots at low but significant
frequencies. This was found previously with the spindle poisons
vinblastine (Graf et al., 1984) and chloral hydrate (Zordan
et al., 1994), as well as with the chelators nitrilotriacetic acid
and (ethylenedinitrilo)tetraacetic acid (Zordan et al, 1990,
1991). Vogel and Nivard (1993) report positive results obtained
in the wAv+ eye spot test with five spindle poisons. However,
as a rule, the aneuploidogenic compounds found positive in
SMART assays have typically shown weak effects. Therefore,
the clear-cut and strong genotoxic effects produced by the
topoisomerase inhibitors in the SMART assays are better
explained by structural DNA damage rather than by impaired
chromosome segregation. In the mwh/TM3 genotype, more-
over, inversion-heterozygosity suppresses reciprocal mitotic
recombination, but would not prevent mitotic non-disjunction.
As wing spot induction in this genotype was not significant with
ellipticine, non-disjunction due to topoisomerase II inhibition
seems not to play a major role in wing spot induction, at least
with respect to this latter compound. However, very minor
contributions by non-disjunction cannot be ruled out com-
pletely in view of the weak but positive responsiveness of the
SMART assays to induced somatic monosomy.
Performance of the SMART method compared with bacterial,
fungal and mammalian test systems
Whereas the SMART assays of Drosophila seem to be good
predictors of mammalian and human genotoxicity of topoiso-
merase inhibitors, there is evidence that bacterial test systems
are not (Gocke, 1991), and that test systems with lower
eukaryotes, such as moulds and yeasts, may have reduced
specificity.
The mould Neurospora crassa, in spite of being a eukaryote,
has shown a type of response more similar to bacteria than to
mammalian cells for compounds such as amsacrine
(m-AMSA), etoposide, teniposide and ellipticine (Gupta,
1990). These compounds are specific for the mammalian
topoisomerase II and show less interaction with gyrase and
therefore are much less potent in bacterial assays (Gupta et al,
1987; Liu, 1989; Gocke, 1991). Inactivity or low activity
seems particularly characteristic for etoposide and teniposide
in bacterial and fungal genotoxicity assays. For instance,
Nakanomyo et al. (1986) have reported very weak mutagenic
effects for these two non-intercalating agents in frameshift
strains (sic!) but not in base substitution strains of the
Salmonella/microsomes test.
The intercalating topoisomerase II inhibitors m-AMSA,
adriamycin and daunorubicin, as well as the non-intercalating
etoposide, have been studied in strain D5 of the yeast S.cerevis-
iae. This test system assesses mitotic crossing over, but also
other endpoints such as conversion and mutation at the adenine-
2 locus. Under growing conditions, the intercalating agents
gave positive results with respect to the total of aberrant
colonies as well as to twin colonies indicative of mitotic
crossing over, but overall the frequency of production of
aberrant colonies was low (Ferguson and Turner, 1988).
However, among the aberrant colonies those due to mitotic
crossing over were relatively frequent compared with those
obtained with other types of genotoxin. Therefore, but particu-
larly also because the non-intercalating etoposide was negative
in this assay, the authors suggested that intercalation is the
activity which is involved in the recombination process.
However, as the two epipodophyllotoxins assayed in the
Drosophila wing spot test were positive for recombinant as
well as non-recombinant spot induction, it rather seems that
insensitivity of yeast, Neurospora and bacteria to the effects
of these compounds is a specific property of the test organisms.
Mechanistic considerations
Recently Ferguson et al (1993) found evidence that in S.cerevi-
siae recombinational repair of damage by intercalating topoiso-
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merase II inhibitors depends on three repair genes.
Recombinational repair of damage produced by the strong
recombinagen DACA particularly required the RAD52 gene
product known to be involved in the recombinational repair
of double-strand breaks.
By analogy we tnay associate the >99% recombinational
origin of wing spots recovered in Drosophila following expo-
sure to ellipticine with the production of double-strand breaks,
which this compound appears to produce almost exclusively
(Pommier et al, 1984). Other compounds which are also
able to induce significant numbers of wing spots of non-
recombinational origin may in part produce other types of
damage. It has been reported for etoposide, for instance, that
it produces a mixture of single- and double-strand breaks, with
a moderate predominance of single-strand breaks (Osheroff,
1989b). Inhibitors show preferences for particular base pair
sequences and stabilize cleavable complexes at compound-
specific sites. The bias for specific bases on the cleaved strand
is generally stronger than for the complementary strand, so
that many sites probably are of the single-strand cleaved type
(Ralph et al, 1994), even in the case of topoisomerase II
inhibition. In contrast to the ellipticines, mitoxantrone has site
specificities similar to those of teniposide (cf. refs in Ferguson
and Baguley, 1994; Ralph et al, 1994).
The topoisomerase I inhibitor camptothecin showed 88% of
the wing spots to be due to recombination and appears as the
next strongest recombinagen after ellipticine among the four
agents investigated in this study (cf. Figure 4c and e). In
yeast, too, camptothecin induces high levels of homologous
recombination and is weakly mutagenic; moreover, cytotoxicity
is more pronounced in strains carrying a defective rad52 repair
gene (Nitiss and Wang, 1988).
There is some similarity in the planar aromatic ring systems
in the chemical structures of ellipticine and camptothecin
(Figure 1), but this feature is probably not the common
determinant cause of high recombinagenicity characterizing
the two compounds. Whereas ellipticine appears to be a perfect
intercalator with specificity for topoisomerase II inhibition,
camptothecin was reported not to bind to DNA and to inhibit
exclusively topoisomerase I in cell-free in vitro reaction
systems (Hsiang et al, 1985). However, more recent studies
suggest that camptothecin nevertheless might have at least
some potential for intercalation but rather into the less common
Z- than B-DNA (Fukada, 1985; Wittig et al, 1989).
Camptothecin trapping topoisomerase I was found to pro-
duce large amounts of DNA single-strand damage in cell-free
in vitro reaction systems (Hsiang et al, 1985), which seems
to contradict the double-strand break hypothesis for the induc-
tion of mitotic crossing over (Ferguson et al, 1993). However,
in cultured human and Drosophila cells, prominent double-
strand as well as single-strand breaks were observed following
treatment with camptothecin (Zhang et al, 1988; Kroeger and
Rowe, 1989). The more pronounced cytotoxicity of campto-
thecin in mutant rad52 yeast strains (Nitiss and Wang, 1988)
may also be related to induced double-strand damage.
It is most conceivable in addition that the relationship
between spot induction by recombinational or other mechan-
isms in the SMART assays is not solely determined by the
nature of the trapped complex but also by additional factors
such as the stability of the ternary complex and the dynamics
of processing of the damage, e.g. during repair. Although we
cannot tell actually how the clones of non-recombinational
origin are produced, we may conclude from the present data
that in this respect there are differences in action between the
topoisomerase inhibitors.
Topoisomerase drugs non-genotoxic in the Drosophila wing
spot test
Not all topoisomerase inhibitors are genotoxic in Drosophila
and induce wing spots. While the poisons of eukaryotic
topoisomerases (Ferguson and Baguley, 1994; Ralph et al,
1994) discussed so far do not prevent cleavage of the DNA but
inhibit religation, other topoisomerase-directed drugs interfere
with cleavage. Certain gyrase-directed bactericidal agents such
as novobiocin or nalidixic acid are weak inhibitors in eukary-
otes but are able to act on eukaryotic topoisomerase n. They
inhibit enzyme-catalysed ATP hydrolysis and prevent formation
of the cleavable complex (Robinson et al, 1993; Ferguson
and Baguley, 1994). Novobiocin is highly bactericidal (Hussy
et al, 1986), but it was not mutagenic in genotoxicity assays
with Salmonella typhimurium or Escherichia coli (McCoy
et al, 1980; Gocke, 1991). When applied alone, this drug did
not induce spots in the wing spot test of Drosophila but did
have modulating antagonistic effects when combined with
monofunctional alkylating agents (Ramel and Magnusson,
1992). In mammalian cells, too, novobiocin alone was unable
to induce enzyme-mediated DNA strand breaks, but did have
cell-cycle-dependent increasing or decreasing modulatory
effects in combination with ionizing radiation or clastogenic
chemicals (Marshall et al, 1983; Takahashi et al, 1985, 1986;
DeMarini et al, 1987b; Dillehay et al, 1987).
The benzo[c]phenantridine alkaloid fagaronine and its con-
gener nitidine have been identified as intercalators (Pezzuto
et al, 1983) inhibiting both types of topoisomerase, but mainly
the type I enzyme (Larsen et al, 1993; Wang et al, 1993).
However, despite intercalation, fagaronine was not genotoxic
in the 5a/mon€//o/microsomes test (strain TM677; Pezzuto
et al, 1983). In the Drosophila wing spot test, fagaronine,
nitidine and several derivatives were negative (P6rez-Chiesa
and Narvaez, 1993; P6rez-Chiesa and Rodriguez, 1993). The
mechanism of topoisomerase inhibition by fagaronine and
congeners is not known, but it may be recalled that there are
other DNA intercalating drugs, such as 9-aminoacridine, which
may interfere with topoisomerase II attachment to DNA
because of inducing helix unwinding and extension. 9-Ami-
noacridine does not function as a topoisomerase II poison, but
on the contrary can act antagonistically against a variety of
topoisomerase II poisons (Ferguson and Baguley, 1994). On
account of the present results we would predict that fagaronine
and its congeners are not potent clastogens or mutagens in
mammalian cells if active at all.
Concluding remarks
With respect to the performance of the SMART methods of
Drosophila, particularly also in genotoxicity testing of agents
which do not react directly with DNA, it is notable that
the wing spot test is sensitive to the genotoxic mammalian
topoisomerase I and topoisomerase II inhibitors, especially
also to the non-intercalating epipodophyllotoxins. As with
other genotoxic agents, the somatic mutant spots induced are
mainly, but not exclusively, due to mitotic recombination. In
this respect, ellipticine appears to be somewhat exceptional,
because it is not common in the wing spot test that genotoxic
agents induce only or almost exclusively recombination events.
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